Status:
COMPLETED
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Non-Small-Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cance...
Eligibility Criteria
Inclusion
- Patients with Non-small cell lung cancer for which the standard cancer treatments of surgery, chemotherapy, radiation or other anticancer drugs are no longer appropriate treatments for you.
Exclusion
- Patients who have had standard cancer treatments of surgery, chemotherapy or other systemic anti-cancer therapy within 4 weeks before start of study therapy.
- Three or more prior chemotherapy regimens.
- Significant cardiovascular events.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
1140 Patients enrolled
Trial Details
Trial ID
NCT00404924
Start Date
November 1 2006
End Date
November 1 2014
Last Update
September 30 2016
Active Locations (102)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tucson, Arizona, United States
2
Research Site
Germantown, Tennessee, United States
3
Research Site
Bahía Blanca, Argentina
4
Research Site
Ciudad de Buenos Aires, Argentina